Lightspeed

Activity from announced rounds

Activity in this selectionOct 22, 2026 · AI · Sep 23, 2026

Lightspeed Venture Partners invests from seed through growth in enterprise, consumer, fintech and healthcare companies, with a global investment platform.

Its sector teams approach different company-building problems: enterprise adoption, changes in consumer behaviour, financial infrastructure and unmet clinical needs. The partnership includes former founders and operators with domain experience, so the relevant team depends on the business being built rather than a single firm-wide industry thesis.

Lightspeed’s healthcare practice focuses on technologies that can improve patient outcomes. In fintech, its stated interests span the financial technology stack, including blockchain, rather than being limited to consumer banking applications.

Sources
Rounds participated in
5
Confirmed lead rounds
2
All roles disclosed
New companies
3
First participation on record · 2 follow-on
Funding in participating rounds
$559M
3 disclosed · full round size, not this investor’s share

By stage

Seed1
Series A1
Series B1
Series C+1
Undisclosed1

By primary sector

Enterprise software2
AI1
Biotech1
Industrial tech1

By country

United States3
1
Germany1

Rounds

5 in this selection
Different

Runs AI demand generation for lean B2B marketing teams, connecting campaign planning, content, channel execution and optimization.

$48MSeed
Participant
Zenzap

Zenzap combines business messaging with shared AI agents that act on team conversations and connected business tools.

UndisclosedSeries A (incremental amount undisclosed)
Lead
Arena

Arena evaluates AI models through comparisons and observations of how people use them in real tasks.

$200MSeries B
Lead
RobCo

Develops AI-driven robotic systems for industrial automation and autonomy

UndisclosedPrimary investment and employee secondary transaction
Participant
Enveda

Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.

$311MSeries E
Participant